Director & 10% Owner Panacea Sells $3.16M in Atara Biotherapeutics Shares

summarizeSummary

A director and 10% owner, Panacea Venture, sold over $3.16 million worth of Atara Biotherapeutics shares, reducing their beneficial ownership to 16.1%.

check_boxKey Events

• Significant Share Sale

  Panacea Venture Healthcare Fund II, L.P. sold 313,446 shares of Common Stock in open market transactions at a weighted average price of $10.0975 per share, totaling approximately $3.16 million.

• Director & 10% Owner Disposition

  The sale was made by entities associated with James Huang, a director and beneficial owner, reducing the Panacea group's aggregate beneficial ownership to 16.1% of outstanding shares.

• Follows Delisting Notice

  This significant disposition occurs shortly after Atara Biotherapeutics received a Nasdaq delisting notice on May 1, 2026, due to failing to meet minimum market value requirements.

• Concurrent Form 4 Filing

  This transaction was also reported in a Form 4 filing on May 11, 2026, confirming the sale by a director and 10% owner.

auto_awesomeAnalysis

Panacea Venture, a significant beneficial owner and associated with a director, sold a substantial block of Atara Biotherapeutics shares. This sale, valued at over $3.16 million, represents a notable reduction in their stake, occurring shortly after the company received a Nasdaq delisting notice and amidst ongoing efforts to address regulatory challenges. This transaction, also reported in a concurrent Form 4, indicates a significant disposition by a key investor.